1. Defective DNAM-1 Dependent Cytotoxicity in Hepatocellular Carcinoma-Infiltrating NK Cells
    Stefania Mantovani et al, 2022, Cancers CrossRef
  2. Diverging prognostic effects of CD155 and CD73 expressions in locally advanced triple-negative breast cancer
    Neslihan Cabioglu et al, 2023, Frontiers in Oncology CrossRef
  3. Primary Resistance to Immunotherapy-Based Regimens in First Line Hepatocellular Carcinoma: Perspectives on Jumping the Hurdle
    Francesca Salani et al, 2022, Cancers CrossRef
  4. Integrated bioinformatic analysis and cell line experiments reveal the significant role of the novel immune checkpoint TIGIT in kidney renal clear cell carcinoma
    Qi-Dong Xia et al, 2023, Frontiers in Oncology CrossRef
  5. TIGIT signaling and its influence on T cell metabolism and immune cell function in the tumor microenvironment
    Nouria Jantz-Naeem et al, 2023, Frontiers in Oncology CrossRef
  6. PVR (CD155) Expression as a Potential Prognostic Marker in Multiple Myeloma
    Byung-Hyun Lee et al, 2022, Biomedicines CrossRef
  7. Aberrant expression of junctional adhesion moleculeā€A contributes to the malignancy of cervical adenocarcinoma by interaction with poliovirus receptor/CD155
    Taro Murakami et al, 2021, Cancer Science CrossRef
  8. Role of CD155/TIGIT in Digestive Cancers: Promising Cancer Target for Immunotherapy
    Daijun Wang et al, 2022, Frontiers in Oncology CrossRef
  9. Peptide-based PET imaging agent of tumor TIGIT expression
    Dinghu Weng et al, 2023, EJNMMI Research CrossRef
  10. Immune-Based Combination Therapies for Advanced Hepatocellular Carcinoma
    Riccardo Carloni et al, 2023, Journal of Hepatocellular Carcinoma CrossRef
  11. A novel scoring system for TIGIT expression in classic Hodgkin lymphoma
    Ombretta Annibali et al, 2021, Scientific Reports CrossRef
  12. Prognostic Role of TIGIT Expression in Patients with Solid Tumors: A Meta-Analysis
    Kunmin Xiao et al, 2021, Journal of Immunology Research CrossRef
  13. Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor
    Luisa Chocarro et al, 2022, Cells CrossRef
  14. Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy
    Hyung-seung Jin et al, 2021, BMB Reports CrossRef